Cempra Inc  

(Public, NASDAQ:CEMP)   Watch this stock  
Find more results for CEMP
-0.06 (-0.18%)
Nov 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 32.32 - 34.24
52 week 13.45 - 46.99
Open 33.06
Vol / Avg. 429,499.00/2.57M
Mkt cap 1.44B
P/E     -
Div/yield     -
EPS -2.07
Shares 43.97M
Beta 0.80
Inst. own 88%
Feb 23, 2016
Q4 2015 Cempra Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 19, 2015
Cempra Inc at Jefferies Global Healthcare Conference
Nov 17, 2015
Cempra Inc at Stifel Healthcare Conference
Oct 22, 2015
Q3 2015 Cempra Inc Earnings Release
Oct 22, 2015
Q3 2015 Cempra Inc Earnings Call - Webcast
Oct 16, 2015
Cempra Inc Conference Call To Discuss Positive Topline Phase 3 Clinical Results for Intravenous Solithromycin
Sep 29, 2015
Cempra Inc at Ladenburg Thalmann Life Sciences Conference
Sep 16, 2015
Cempra Inc at Morgan Stanley Healthcare Conference
Sep 10, 2015
Cempra Inc at Robert W Baird and Co Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -1104.26% -405.16%
Operating margin -1077.08% -390.38%
EBITD margin - -389.88%
Return on average assets -56.03% -60.35%
Return on average equity -73.76% -94.12%
Employees 55 -
CDP Score - -


6320 Quadrangle Dr Ste 360
CHAPEL HILL, NC 27517-7890
United States - Map
+1-919-5762306 (Phone)
+1-302-5313150 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Cempra Inc. is a clinical-stage pharmaceutical company focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Company's lead product, solithromycin, is being developed in oral capsules, intravenous, or IV, and suspension formulations, initially for the treatment of community acquired bacterial pneumonia, or CABP, an infection of the respiratory tract. The Company's second product is Taksta, an antibiotic known as fusidic acid, that has been used for decades outside the United States, including Western Europe, but , which has never been approved in the United States. The Company is developing Taksta in the United States as an oral treatment of refractory bone and joint infections caused by staphylococci.

Officers and directors

Garheng Kong M.D., Ph.D. Independent Chairman of the Board
Age: 40
Bio & Compensation  - Reuters
Prabhavathi B. Fernandes Ph.D. President, Chief Executive Officer, Director
Age: 66
Bio & Compensation  - Reuters
Mark W. Hahn Chief Financial Officer, Executive Vice President
Bio & Compensation  - Reuters
David S. Moore Executive Vice President, Chief Commercial Officer
Age: 41
Bio & Compensation  - Reuters
David W. Oldach Chief Medical Officer
Age: 57
Bio & Compensation  - Reuters
Michael R. Dougherty Independent Director
Age: 57
Bio & Compensation  - Reuters
David N. Gill Independent Director
Age: 60
Bio & Compensation  - Reuters
Dov A. Goldstein M.D. Independent Director
Age: 47
Bio & Compensation  - Reuters
John H. Johnson Independent Director
Age: 57
Bio & Compensation  - Reuters
Richard S. Kent M.D. Independent Director
Age: 65
Bio & Compensation  - Reuters